Lumenis Ltd., which raised nearly $100 million through an initial public offering on NASDAQ last year, is in talks to be acquired by Chinese conglomerate Fosun for nearly $500 million, according to the Israeli financial newspaper Calcalist.
The paper reported that Fosun officials had made initial contact with executives from Yokneam, Israel-based Lumenis, who indicated that they would accept an offer of $480 million for the company, a 26% premium over its current market value.
A Fosun spokeswoman in Beijing and Lumenis Corporate Marketing Director Sigal Deutsch both told Reuters news servicethat their respective companies do not comment on market rumors.
Lumenis went public on the NASDAQ stock exchange last February, raising just over $94 million through its IPO.
In November 2013, Lumenis won clearance in the U.S. and Japan for its Array LaserLink pattern scanning device for multi-spot retinal laser treatment. Earlier in 2013, the FDA slapped the company with a Class I recall of its VersaCut morcellator.